MedTrace Logo

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

NCT06171685 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-07-15

No results posted yet for this study

Summary

This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol.

The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.

Conditions

  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

DRUG

Teclistamab Monotherapy

standard of care

DRUG

Teclistamab

investigational doses compared to SOC

Sponsors & Collaborators

  • Multiple Myeloma Research Consortium

    lead NETWORK

Principal Investigators

  • Hearn J Cho, MD, PhD · Multiple Myeloma Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-17
Primary Completion
2029-07-31
Completion
2030-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06171685 on ClinicalTrials.gov